Savolitinib vs. Sunitinib in MET-driven PRCC.
AstraZeneca
AstraZeneca
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
Alliance for Clinical Trials in Oncology
Eastern Cooperative Oncology Group
NRG Oncology
Telix Pharmaceuticals (Innovations) Pty Limited
EMD Serono
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Hoffmann-La Roche
Sun Yat-sen University
Merck Sharp & Dohme LLC
AstraZeneca
Merck Sharp & Dohme LLC
Ankara University
Eisai Inc.
SWOG Cancer Research Network
Merck Sharp & Dohme LLC
Bristol-Myers Squibb
Wake Forest University Health Sciences
Sun Yat-sen University
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC
Bristol-Myers Squibb
SWOG Cancer Research Network
Exelixis
Peking University Cancer Hospital & Institute
SWOG Cancer Research Network
Assistance Publique - Hôpitaux de Paris
AVEO Pharmaceuticals, Inc.
Merck Sharp & Dohme LLC
Pfizer
Incyte Corporation
Tampere University Hospital
Bristol-Myers Squibb
Bristol-Myers Squibb
NRG Oncology
UNICANCER
University Hospital, Bordeaux
AstraZeneca
Merck Sharp & Dohme LLC
Xynomic Pharmaceuticals, Inc.
Novartis
AIO-Studien-gGmbH
Gustave Roussy, Cancer Campus, Grand Paris
Telix Pharmaceuticals (Innovations) Pty Limited
Bristol-Myers Squibb